Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion. This article aims to review the latest literature on intra-arterial locoregional therapies for treating ICC.
Areas Covered: A literature search was conducted on PubMed using keywords: intrahepatic cholangiocarcinoma, intra-arterial locoregional therapy, embolization, chemoembolization, radioembolization, hepatic artery infusion, and immunotherapy. Articles from 2008 to 2024 were reviewed. Survival data from retrospective and prospective studies, meta-analyses, and clinical trials were evaluated.
Expert Opinion: Although no level I evidence supports the superiority of any specific intra-arterial therapy, there has been a shift toward favoring radioembolization. In our expert opinion, radioembolization may offer superior outcomes when performed by skilled operators with meticulous planning and personalized dosimetry, particularly for radiation segmentectomy or treating lobar/bilobar disease in appropriate candidates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17474124.2024.2402358 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cisplatin intra-arterial chemotherapy for recurrent maxillary gingival cancer and metastatic lymph nodes without radiation or surgery: A case report.
Radiol Case Rep
January 2025
Department of Radiology, Sapporo Medical University School of Medicine, South 1 West 17, Chuo-Ku, Sapporo City, Hokkaido 060-8556, Japan.
Most patients with head and neck cancers struggle with their treatment, particularly those with recurrent cancer. However, there is no consensus on effective treatments for recurrent head and neck cancer. Recurrent cases are often challenging to treat because performing both reirradiation and surgical intervention can occasionally be difficult.
View Article and Find Full Text PDFIntraarterial Chemotherapy for Liver Metastases.
Hematol Oncol Clin North Am
February 2025
Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10th floor, New York, NY 10065, USA. Electronic address:
Colorectal cancer (CRC) is one of the leading cancers globally in terms of both incidence and cancer-related mortality. Liver metastatic disease is the main prognostic driver for patients with CRC. The management options for liver metastatic CRC continue to evolve, particularly with the incorporation of locoregional therapies into the treatment paradigm.
View Article and Find Full Text PDFAdvances in the management of regionally metastatic melanoma.
Surg Oncol
December 2024
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa FL, USA. Electronic address:
Article Synopsis
- Patients with locoregionally advanced melanoma still face a poor prognosis despite new systemic therapies.
- Direct delivery of treatment through intralesional injections and intra-arterial infusions reduces side effects and improves effectiveness.
- Recent advancements include approved and trialed therapies like Talimogene laherparepvec (T-VEC), PV-10, TAVOkinase/electrocorporation, and percutaneous hepatic perfusion (PHP) for treating melanoma.
Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.
Expert Rev Gastroenterol Hepatol
September 2024
Division of Vascular and Interventional Radiology, Department of Radiology, The Georgetown University Medical Center, Washington, DC, USA.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion.
View Article and Find Full Text PDFClinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
Ann Surg Oncol
November 2024
Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: Locoregional treatment with transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC) and systemic targeted immunotherapy with tyrosine kinase inhibitors (TKI) and programmed cell death protein-1 (PD-1) inhibitors in the treatment of unresectable hepatocellular carcinoma (uHCC) have achieved promising efficacy. The retrospective study aimed to evaluate the efficacy and safety of TACE and HAIC plus TKI with or without PD-1 for uHCC.
Patients And Methods: From November 2020 to February 2024, the data of 44 patients who received TACE-HAIC + TKI + PD-1 (THKP group) and 34 patients who received TACE-HAIC + TKI (THK group) were retrospectively analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!